Intrinsic Value of S&P & Nasdaq Contact Us
English English 中文(简) 中文(简) 中文(繁) 中文(繁) हिन्दी हिन्दी Español Español 日本語 日本語 한국어 한국어 Deutsch Deutsch Français Français
← Back to all stocks

Acceleron Pharma Inc. XLRN NASDAQ

NASDAQ Global Market • Healthcare • Biotechnology • US • USD

SharesGrow Score
39/100
1/7 Pass
SharesGrow Intrinsic Value
N/A
Negative cash flow
Analyst Price Target
$150.00
-16.1%

Acceleron Pharma Inc. (XLRN) is a Biotechnology company in the Healthcare sector, currently trading at $178.75. It has a SharesGrow Score of 39/100, indicating a weak investment profile with 1 out of 7 criteria passed.

Analyst consensus target is XLRN = $150 (-16.1% upside).

Financials: revenue is $93M, +152.6%/yr average growth. Net income is $166M (loss), growing at -15.9%/yr. Net profit margin is -179.4% (negative). Gross margin is 100% (+0 pp trend).

Balance sheet: total debt is $24M against $855M equity (Debt-to-Equity (D/E) ratio 0.03, conservative). Current ratio is 14.85 (strong liquidity). Debt-to-assets is 2.6%. Total assets: $932M.

Analyst outlook: 18 / 26 analysts rate XLRN as buy (69%) — moderate consensus.

SharesGrow 7-Criteria breakdown: Value 20/100 (Fail), Growth 58/100 (Partial), Past 0/100 (Fail), Health 100/100 (Pass), Moat 46/100 (Partial), Future 37/100 (Fail), Income 10/100 (Fail).

$150.00
▼ 16.08% Downside
Average Price Target
Based on 26 Wall Street analysts offering 12-month price targets for Acceleron Pharma Inc., the average price target is $150.00, with a high forecast of $160.00, and a low forecast of $139.00.
Highest Price Target
$160.00
Average Price Target
$150.00
Lowest Price Target
$139.00

XLRN SharesGrow Score Overview

45/100
SharesGrow Score
Mixed signals — some strengths
View full scorecard →
VALUE 20/100
Valuation — P/E, PEG, Forward PEG
GROWTH 58/100
Financials — average growth
PAST 0/100
strong — trend
HEALTH 100/100
Balance sheet — Debt-to-Equity (D/E) ratio, Current ratio is
MOAT 46/100
Gross margin is + market cap
FUTURE 37/100
Analyst outlook — as buy
INCOME 10/100
Net profit margin is
Scores derived from financial statements, analyst ratings, and balance sheet data.

Score Breakdown — XLRN

✗
VALUE Fail
20/100
XLRN trades at a trailing Price-to-Earnings (P/E) of N/A (S&P 500 average ~25). Analyst consensus target is $150, implying -16.1% from the current price $179. Composite: Price-to-Earnings (20%) + Forward Price/Earnings-to-Growth (35%) + upside (25%) + trailing PEG (20%). ≥ 60 = Pass.
View details →
~
GROWTH Partial
58/100
XLRN: +152.6%/yr revenue is, -15.9%/yr Net income is average growth. mixed. Score: >20%/yr = 100, >10% = 80, >5% = 65, >0% = 45, < 0 = 15.
View details →
—
PAST N/A
N/A
No analyst coverage available for this stock.
✓
HEALTH Pass
100/100
Balance sheet XLRN: Debt-to-Equity (D/E) ratio 0.03 (conservative), Current ratio is 14.85 (strong liquidity). Debt-to-Equity < 0.5, Current Ratio > 1.5, Interest Coverage > 8x = ideal. ≥ 70 = Pass.
View details →
~
MOAT Partial
46/100
XLRN: Gross margin is 100% (+0 pp trend), N/A market cap. Moat (0-100): margin (35%) + trend (15%) + market cap (30%) + revenue is (20%). Score 46/100. ≥ 70 = Pass.
View details →
✗
FUTURE Fail
37/100
Analyst outlook: 18 / 26 analysts rate XLRN as buy (69%). Analyst consensus target is $150 (-16.1% upside). Score: 60% buy consensus + 40% upside. ≥ 60 = Pass.
View details →
✗
INCOME Fail
10/100
XLRN: Net profit margin is -179.4%. negative. Score: ≥30% = 100, ≥20% = 85, ≥15% = 70, ≥10% = 55, ≥5% = 45, ≥0% = 30, < 0 = 10.
View details →

Stock Chart & Stats

Market Data
52-Week Range177.2-179.85
Volume7.88M
Avg Volume (30D)1.27M
Beta (1Y)0.13
Share Statistics
EPS (TTM)-2.92
Shares Outstanding$56.8M
IPO Date2013-09-18
Employees312
CEOHabib Dable
Financial Highlights & Ratios
Revenue (TTM)$92.52M
Gross Profit$92.52M
EBITDA$-162.16M
Net Income$-166.03M
Operating Income$-167.31M
Total Cash$849.9M
Total Debt$24.08M
Net Debt$-646.88M
Total Assets$932.34M
Price / Earnings (P/E)-61.2
Analyst Forecast
1Y Price Target$151.00
Target High$160.00
Target Low$139.00
Upside-15.5%
Rating ConsensusBuy
Analysts Covering26
Buy 69% Hold 27% Sell 4%
Company Info
CountryUS
ExchangeNASDAQ Global Market
CurrencyUSD
ISINUS00434H1086

Price Chart

Track all markets on TradingView
XLRN
Acceleron Pharma Inc. ↗  ·  NASDAQ Global Market
Healthcare • Biotechnology
177.20 52WK RANGE 179.85

People Also View

LLY
LLY
Eli Lilly and Company
$922.50
-0.76%
 JNJ
JNJ
Johnson & Johnson
$240.10
+0.90%
 ABBV
ABBV
AbbVie Inc.
$210.32
+1.86%
 RHHBF
RHHBF
Roche Holding AG
$418.50
+1.82%
 RHHBY
RHHBY
Roche Holding AG
$51.02
+0.65%
 AZN
AZN
AstraZeneca PLC
$204.38
+1.06%
 NVSEF
NVSEF
Novartis AG
$156.48
+0.00%
 MRK
MRK
Merck & Co., Inc.
$119.96
-0.16%
Contact Us
🎓
SharesGrow Academy
Learn how to calculate Intrinsic Value and find undervalued stocks.
Weekly live sessions
📧 [email protected]
📞 +65 8912 8000
Send us a message